Literature DB >> 27999761

Novel immunotherapy for adult T-cell leukemia/lymphoma: Targeting aurora kinase A.

Nicholas Paul Casey1, Hiroshi Fujiwara1, Toshiki Ochi1, Masaki Yasukawa1.   

Abstract

Adult T-cell leukemia/lymphoma is caused by infection with HTLV-1, following a long latent period. Immunotherapy targeting Aurora kinase A, a tumor-associated antigen over-expressed in adult T-cell leukemia/lymphoma, holds great therapeutic potential. We review the evidence in favor of a therapeutic strategy combining vaccination and TCR-gene transfer against this target.

Entities:  

Keywords:  Adult T-cell leukemia/lymphoma; T-cell receptor gene; aurora kinase A; engineered T cell; immunotherapy

Year:  2016        PMID： 27999761      PMCID： PMC5139639          DOI： 10.1080/2162402X.2016.1239006

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Cancer stem cells and their mechanism of chemo-radiation resistance.

Authors:  Yonghyun Kim; Kyeung Min Joo; Juyoun Jin; Do-Hyun Nam
Journal:  Int J Stem Cells       Date:  2009-05       Impact factor: 2.500

2.  Regulatory T-cell function of adult T-cell leukemia/lymphoma cells.

Authors:  Hiroki Yano; Takashi Ishida; Atsushi Inagaki; Toshihiko Ishii; Shigeru Kusumoto; Hirokazu Komatsu; Shinsuke Iida; Atae Utsunomiya; Ryuzo Ueda
Journal:  Int J Cancer       Date:  2007-05-01       Impact factor: 7.396

3.  Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro.

Authors:  Mariko Tomita; Naoki Mori
Journal:  Cancer Sci       Date:  2010-01-19       Impact factor: 6.716

4.  Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity.

Authors:  Kozo Nagai; Toshiki Ochi; Hiroshi Fujiwara; Jun An; Toshiaki Shirakata; Junichi Mineno; Kiyotaka Kuzushima; Hiroshi Shiku; J Joseph Melenhorst; Emma Gostick; David A Price; Eiichi Ishii; Masaki Yasukawa
Journal:  Blood       Date:  2011-10-24       Impact factor: 22.113

5.  Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma.

Authors:  Hiroyoshi Nishikawa; Yuka Maeda; Takashi Ishida; Sacha Gnjatic; Eiichi Sato; Fumiko Mori; Daisuke Sugiyama; Asahi Ito; Yasuo Fukumori; Atae Utsunomiya; Hiroshi Inagaki; Lloyd J Old; Ryuzo Ueda; Shimon Sakaguchi
Journal:  Blood       Date:  2012-02-08       Impact factor: 22.113

Review 6.  Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.

Authors:  Marcus Remer; Aymen Al-Shamkhani; Martin Glennie; Peter Johnson
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

7.  Aurora-A kinase: a novel target of cellular immunotherapy for leukemia.

Authors:  Toshiki Ochi; Hiroshi Fujiwara; Koichiro Suemori; Taichi Azuma; Yoshihiro Yakushijin; Takaaki Hato; Kiyotaka Kuzushima; Masaki Yasukawa
Journal:  Blood       Date:  2008-09-26       Impact factor: 22.113

Review 8.  Aurora kinase A inhibitors: promising agents in antitumoral therapy.

Authors:  Marcos Malumbres; Ignacio Pérez de Castro
Journal:  Expert Opin Ther Targets       Date:  2014-09-09       Impact factor: 6.902

9.  Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia.

Authors:  Yukihiro Miyazaki; Hiroshi Fujiwara; Hiroaki Asai; Fumihiro Ochi; Toshiki Ochi; Taichi Azuma; Takashi Ishida; Sachiko Okamoto; Junichi Mineno; Kiyotaka Kuzushima; Hiroshi Shiku; Masaki Yasukawa
Journal:  Blood       Date:  2013-05-02       Impact factor: 22.113

Review 10.  Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma.

Authors:  Koji Kato; Koichi Akashi
Journal:  Viruses       Date:  2015-12-14       Impact factor: 5.048
  10 in total
  3 in total

Review 1.  T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.

Authors:  Melinda A Biernacki; Michelle Brault; Marie Bleakley
Journal:  Cancer J       Date:  2019 May/Jun       Impact factor: 3.360

2.  Developing new ceramide analogs and identifying novel sphingolipid-controlled genes against a virus-associated lymphoma.

Authors:  Jungang Chen; Navneet Goyal; Lu Dai; Zhen Lin; Luis Del Valle; Jovanny Zabaleta; Jiawang Liu; Steven R Post; Maryam Foroozesh; Zhiqiang Qin
Journal:  Blood       Date:  2020-11-05       Impact factor: 22.113

3.  Bone marrow expands the repertoire of functional T cells targeting tumor-associated antigens in patients with resectable non-small-cell lung cancer.

Authors:  Seyer Safi; Yoshikane Yamauchi; Slava Stamova; Anchana Rathinasamy; Jan Op den Winkel; Simone Jünger; Mariana Bucur; Ludmilla Umansky; Arne Warth; Esther Herpel; Martin Eichhorn; Hauke Winter; Hans Hoffmann; Philipp Beckhove
Journal:  Oncoimmunology       Date:  2019-10-23       Impact factor: 8.110
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.